Accumulating evidence has confirmed that ACSL4 can enhance the sensitivity of cancer cells to drug treatment by promoting ferroptosis, such as renal cell carcinoma [63] and colorectal cancer [64]. This evidence concerns the gene ACSL4 and hereditary clear cell renal cell carcinoma.